Apollo Therapeutics Announces Second Close Of Series C Financing Bringing Total Raised In Round To $260 Million
Round Type
Series C
CambridgeBiotechnologyPharmaceuticalBiopharmaBiotechnology ResearchInvestors
Description
Apollo Therapeutics (“Apollo” or “the Company”), a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million.
Quick answer
Apollo Therapeutics Group Limited raised an undisclosed amount in a Series C round, dated January 2, 2024. Investors: Rock Springs Capital, M&G Plc and Patient Square Capital. Apollo Therapeutics Group Limited is based in Cambridge, Maryland, United States.
- How much did Apollo Therapeutics Group Limited raise?
- Apollo Therapeutics Group Limited raised an undisclosed amount in a Series C round on January 2, 2024.
- Who invested in Apollo Therapeutics Group Limited?
- Rock Springs Capital, M&G Plc and Patient Square Capital are named as investors in this round.
- What does Apollo Therapeutics Group Limited do?
- Apollo Therapeutics Group Limited (“Apollo”), the portfolio biopharmaceutical company, and Sunshine Lake Pharma Co., Ltd. (“Sunshine Lake”), an innovative pharmaceutical company and a member of HEC Group.
- Where is Apollo Therapeutics Group Limited based and how big is it?
- Apollo Therapeutics Group Limited is based in Cambridge, Maryland, United States. Fundz records about 57 employees.
- Who are the decision-makers at Apollo Therapeutics Group Limited?
- Fundz holds 1 contact at Apollo Therapeutics Group Limited. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Pharmaceutical and Biopharma around the same time
Companies in the same sectors as Apollo Therapeutics Group Limited that raised within 45 days of this round, from Fundz verified event records.
- Sudo Biosciences raised $147M (Series B) on February 13, 2024.
- Attralus raised $56M (Funding Round) on February 7, 2024.
- Attralus raised $56M on January 26, 2024.
- OnCusp Therapeutics raised $100M (Series A) on January 4, 2024.
- Liquidia raised $100M (Funding Round) on January 4, 2024.
- Biodexa Pharmaceuticals raised $6.8M on December 21, 2023.
Who to call at Apollo Therapeutics Group Limited, and when
A new round usually means Apollo Therapeutics Group Limited is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Apollo Therapeutics Group Limited raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Apollo Therapeutics Group Limited, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Apollo Therapeutics Group Limited. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Apollo Therapeutics Group Limited raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Apollo Therapeutics Group Limited raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.